Why the study?
Does routine cancer screening in elderly patients with DVT modify middle-term mortality and cancer diagnosis outcomes?
Does routine cancer screening in elderly patients with DVT modify middle-term mortality and cancer diagnosis outcomes?
Cancer diagnosis at the time of DVT does not modify middle-term outcomes in patients aged 75 years and older, suggesting that systematic cancer screening in this older population may be unjustified.
Comparable mortality leaves screening benefit open in elderly DVT; hypothesis-generating, prospective trials needed.
Objectives: To assess whether cancer screening in elderly patients with deep venous thrombosis (DVT) could modify their outcome. Design: Prospective, case-control study. Setting: Department of internal medicine and gerontology at Angers University Hospital, from february 1999 to january 2000. The 5.8-year-follow-up was realized by means of postal questionnaires sent to patients’ family doctors. Participants: One hundred and eighteen DVT patients hospitalized for DVT were recruited and stratified into two groups (A and B) according to the age of 75 years and matched for 118 controls (groups C and D). Measurements: DVT was confirmed by a venous ultrasonography and cancer was screened by routine investigations. Outcome measures over 5.8 years: mortality rate and cancer diagnosis.Results: Cancer diagnosis during hospitalization was comparable between groups (A: 10.2% vs C: 5.1%, p = 0.488; B: 8% vs D: 0%, p = 0.06). After discharge, it was similar (A and C: 5.1%; B and D: 3.4%). Cancer related deaths were not “statistically” different (A: 6/21 vs C: 5/23, p = 0.85; B: 6/8 vs D: 1/5, p = 0.103). Mortality ratios were comparable (A: 35.6% vs C: 39%, p = 0.849; B: 13.5% vs D: 8.5%, p = 0.555), but a high mortality was noted in the group B as compared with group C (57% vs 8%; p = 0.0006) in the first year following DVT. Conclusion: Cancer diagnosis at the time of DVT does not modify outcomes of patients aged 75 years and older. Hence, a systematic screening for cancer among older patients could be unjustified. Other case-control studies are necessary to validate these results.
No takes yet. Share an insight, caveat, or question.
Ghali et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: